[go: up one dir, main page]

WO2003028001A3 - Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol - Google Patents

Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol Download PDF

Info

Publication number
WO2003028001A3
WO2003028001A3 PCT/KR2002/001780 KR0201780W WO03028001A3 WO 2003028001 A3 WO2003028001 A3 WO 2003028001A3 KR 0201780 W KR0201780 W KR 0201780W WO 03028001 A3 WO03028001 A3 WO 03028001A3
Authority
WO
WIPO (PCT)
Prior art keywords
flavopiridol
tnf
cancer cell
tnf family
family proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2002/001780
Other languages
French (fr)
Other versions
WO2003028001A8 (en
WO2003028001A2 (en
Inventor
Shin-Wu Jeong
Dong-Myung Kim
Sung-Young Koo
Jin-Ho Lee
Chang-Yong Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Priority to AU2002334433A priority Critical patent/AU2002334433A1/en
Publication of WO2003028001A2 publication Critical patent/WO2003028001A2/en
Publication of WO2003028001A8 publication Critical patent/WO2003028001A8/en
Publication of WO2003028001A3 publication Critical patent/WO2003028001A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a cancer cell- specific apoptosis inducing composition. The TNF (tumor necrosis factor; hereinafter, referred to as ' TNF ') family proteins and flavopiridol (also its salts) and the like are individually disadvantageous to provoke a serious side effect such as toxicity against an excessive dose, although they have excellent anti-cancer effects respectively. The composition of the present invention is prepared by combining the TNF family protein and flavopiridol, which reduces the toxicity or the side effect induced during the independent treatment at an high concentration, since the TNF family protein and flavopiridol are blended at an low concentration. Also, the composition has a specific action for cancer cells and a synergistic efficacy pharmaceutically.
PCT/KR2002/001780 2001-09-24 2002-09-19 Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol Ceased WO2003028001A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002334433A AU2002334433A1 (en) 2001-09-24 2002-09-19 Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR2001-0059058 2001-09-24
KR1020010059058A KR20030026069A (en) 2001-09-24 2001-09-24 Apoptosis-inducing cancer-cell-specific composition by combination with TNF family protein and flavopiridol

Publications (3)

Publication Number Publication Date
WO2003028001A2 WO2003028001A2 (en) 2003-04-03
WO2003028001A8 WO2003028001A8 (en) 2003-05-08
WO2003028001A3 true WO2003028001A3 (en) 2003-12-04

Family

ID=19714614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2002/001780 Ceased WO2003028001A2 (en) 2001-09-24 2002-09-19 Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol

Country Status (3)

Country Link
KR (1) KR20030026069A (en)
AU (1) AU2002334433A1 (en)
WO (1) WO2003028001A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2356880B8 (en) 2009-08-21 2012-10-30 Universidad De Zaragoza LIPOSOMES COVERED WITH THE EXTRACELLULAR DOMAIN OF THE APO2L / TRAIL PROTEIN.
US20180280407A1 (en) * 2014-11-07 2018-10-04 Tolero Pharmaceuticals, Inc. Methods to target transcriptional control at super-enhancer regions
EP3611506B1 (en) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
AU2016264212B2 (en) 2015-05-18 2020-10-22 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
RU2759963C2 (en) 2015-08-03 2021-11-19 Сумитомо Даиниппон Фарма Онколоджи, Инк. Combination therapies for the treatment of cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR20190099260A (en) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. Profiling Peptides and Methods for Sensitivity Profiling
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
KR20210099066A (en) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. CDK9 inhibitors and polymorphs thereof for use as agents for the treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN110876741B (en) * 2019-11-25 2020-09-29 郑州大学第一附属医院 GBE1 inhibitor frataxin and application of pharmaceutical composition thereof in preparation of drugs for treating lung adenocarcinoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US6087366A (en) * 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
US5750495A (en) * 1996-03-26 1998-05-12 The Regents Of The University Of California Treatment of cystic disease with TNF-α
JP2000514456A (en) * 1996-07-15 2000-10-31 ブリストル―マイヤーズ・スクイブ・カンパニー Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
NAGANE M. ET AL: "The potential of TRAIL for cancer chemotherapy.", APOPTOSIS, vol. 6, no. 3, June 2001 (2001-06-01), pages 191 - 197 *
SARTORIUS U. ET AL: "Molecular mechanisms of death-receptor-mediated apoptosis.", CHEMBIOCHEM., vol. 2, no. 1, January 2001 (2001-01-01), pages 20 - 29, XP002955776, DOI: doi:10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.0.CO;2-X *
SHAPIRO G.I. ET AL: "A phase II trail of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.", CLIN. CANCER RES., vol. 7, no. 6, June 2001 (2001-06-01), pages 1590 - 1599 *
SHAPIRO G.I. ET AL: "Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell line.", CLIN. CANCER RES., vol. 5, no. 10, October 1999 (1999-10-01), pages 2925 - 2938 *
VAN OPHOVEN A. ET AL: "Tumor necrosis factor-related apoptosis-inducine ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature", PROSTATE CANCER PROSTATIC DIS., vol. 2, no. 5 + 6, December 1999 (1999-12-01), pages 227 - 233 *
WANG H.K.: "Flavopiridol. National Cancer Institute.", CURR. OPIN. INVESTIG. DRUGS, vol. 2, no. 8, August 2001 (2001-08-01), pages 1149 - 1155, XP008073764 *

Also Published As

Publication number Publication date
WO2003028001A8 (en) 2003-05-08
WO2003028001A2 (en) 2003-04-03
AU2002334433A1 (en) 2003-04-07
KR20030026069A (en) 2003-03-31

Similar Documents

Publication Publication Date Title
WO2005077344A3 (en) Hydantoin derivatives as inhibitors of cellular necrosis
EA200500893A1 (en) TRICYCLIC COMPOUNDS, REPRESENTING PROTECTION KINASE INHIBITORS, TO INCREASE THE EFFECTIVENESS OF ANTI-TUMOR AGENTS AND RADIATIVE THERAPY
AU747599C (en) Antitumor agents
CA2505128A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
WO2003061768A3 (en) Use of a compound inactivating the kinase a protein in a composition containing a cosmetically acceptable medium in order to lighten the skin
WO2004069190A3 (en) Combination therapy for treating protein deficiency disorders
EP2561874A3 (en) Pharmaceutical compositions for treating cancer
EP2460522A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
EA200600209A1 (en) PYRROLO [3,4-c] DERIVATIVES OF PYRAZOLE, ACTIVATED AS KINASE INHIBITORS
BR0309343A (en) Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions.
IL173348A (en) Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments
UY28310A1 (en) PIRAZOLES AS TUMOR NECROSIS FACTOR INHIBITORS
DE69834923D1 (en) Hochgradig lipophile camptothecin-derivate
BR0309342A (en) Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions.
WO2003028001A3 (en) Method and pharmaceutical composition for inducing cancer cell-specific apoptosis by combination with tnf family proteins and flavopiridol
PL342614A1 (en) Anticarcinogenic drugs
WO2003008430A3 (en) Porphyrin derivatives for photodynamic therapy
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2007056264A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
WO2000001415A3 (en) Use of inhibitors of protein kinase c epsilon to treat pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 11/2003 CLASSEE 14/2003 REPLACE ""A1"" BY ""A2"" AND UNDER ""PUBLISHED"", REPLACE ""WITH INTERNATIONAL SEARCH REPORT"" BY ""WITHOUT INTERNATIONAL SEARCH REPORT""

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP